背景:BRAFV600E突变与结直肠癌(CRC)患者的不良预后相关。但在CRC患者中,V600E和非V600E突变的临床病理特征的比较并不为人所知.这项研究的目的是评估临床和病理特征,BRAF突变在CRC中的预后价值。方法:我们进行了一项回顾性研究,以描述BRAF突变CRC患者的临床和病理特征以及生存率。根据BRAF状态将患者分类为BRAFV600E突变和非V600E突变。分析两组患者特征及生存情况的差异。结果:性别无显著性差异,家族史,原发肿瘤的位置,具有BRAF-V600E突变和非V600E突变的患者之间的转移位点。V600E突变患者比非V600E突变患者年轻(p=0.002)。BRAFV600E突变患者比非V600E突变患者的预后较差(23.1vs.49.9个月,分别,p=0.0024)。缺乏CDX2表达与预后较差相关(mOS:9.4mvs.没有到达,分别,p=0.016)。V600E突变状态不影响一线或二线治疗的mPFS和ORR。结论:BRAFV600E突变定义了预后较差的CRC的独特亚组。缺乏CDX2表达与不良OS相关。V600E突变状态不影响一线或二线治疗的mPFS。
Background: BRAF V600E mutation is associated with poor prognosis of colorectal cancer (CRC) patients, but the comparison of clinic-pathologic features between
V600E and non-
V600E mutation was not well-known in CRC patients. The aim of this study is to evaluate the clinical and pathological features, prognostic value of BRAF mutations in CRC. Methods: We conducted a retrospective study to characterize the clinical and pathological features and survival of patients with BRAF mutated CRC. Patients were classified according to BRAF status as BRAF
V600E mutation and non-
V600E mutations. Difference of characteristics and survival between the two groups was analyzed. Results: There was no significant difference in gender, family history, location of primary tumor, metastatic sites between patients with BRAF-V600E mutation and non-
V600E mutations. Patients with
V600E mutation were younger than those with non-
V600E mutations (p = 0.002). Patients with BRAF
V600E mutation showed a poorer outcome than those with non-
V600E mutations (23.1 vs. 49.9 months, respectively, p = 0.0024). Lack of CDX2 expression was associated with worse prognosis (mOS: 9.4 m vs. not reached, respectively, p = 0.016). Status of V600E mutation did not affect the mPFS and ORR of first-line or second-line treatment. Conclusion: BRAF V600E mutation defines a distinct subgroup of CRC with worse prognosis. Lack of CDX2 expression is associated with poor OS. Status of V600E mutation did not affect the mPFS of first-line or second-line treatment.